August 14, 2019 / Clinical Trials

Catabasis Shares August 2019 Newsletter

Catabasis shares the latest edition of their community newsletter, including an update on the Phase 3 PolarisDMD trial which is enrolling boys affected by Duchenne ages 4 to 7, any mutation type, that are not on steroids.

Click here to download (PDF).

Join Our Mailing List